DrugPatentWatch Database Preview
Drugs in Development Information for Fotemustine
» See Plans and Pricing
What is the drug development status for Fotemustine?
Fotemustine is an investigational drug.
There have been 16 clinical trials for Fotemustine.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.
There are two US patents protecting this investigational drug and thirty-one international patents.
Summary for Fotemustine
| US Patents | 2,725 |
| International Patents | 31,707 |
| US Patent Applications | 7,226 |
| WIPO Patent Applications | 32 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2012-06-01) |
| Vendors | 65 |
Recent Clinical Trials for Fotemustine
| Title | Sponsor | Phase |
|---|---|---|
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | Mingzhi Zhang | Phase 4 |
| A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT | Genenta Science | Phase 1/Phase 2 |
| MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | Azienda Sanitaria di Firenze | Phase 2/Phase 3 |
Clinical Trial Summary for Fotemustine
Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine
US Patents for Fotemustine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fotemustine | Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | Start Trial |
| Fotemustine | Start Trial | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Fotemustine | Start Trial | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | Start Trial |
| Fotemustine | Start Trial | Anti-FGFR3 antibodies and methods using same | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fotemustine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fotemustine | World Intellectual Property Organization (WIPO) | 2015148714 | 2034-03-25 | Start Trial |
| Fotemustine | Australia | 2015231053 | 2034-03-21 | Start Trial |
| Fotemustine | Brazil | 112016021620 | 2034-03-21 | Start Trial |
| Fotemustine | Canada | 2943339 | 2034-03-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
